White House Names Monica Bertagnolli as NCI Director
The announcement confirms earlier reports that Bertagnolli will become the first woman to lead the National Cancer Institute since its founding in 1937.
White House Names Monica Bertagnolli as NCI Director
White House Names Monica Bertagnolli as NCI Director
The announcement confirms earlier reports that Bertagnolli will become the first woman to lead the National Cancer Institute since its founding in 1937.
The announcement confirms earlier reports that Bertagnolli will become the first woman to lead the National Cancer Institute since its founding in 1937.
Ryan Layer, The Conversation | May 27, 2022 | 5 min read
Tumors contain thousands of genetic changes, but only a few are actually cancer-causing. A quicker way to identify these driver mutations could lead to more targeted cancer treatments.
Alejandra Manjarrez, PhD | Aug 27, 2021 | 4 min read
In a retrospective analysis, a team found that an algorithm integrating the gene expression of a tumor with the radiation dose a patient received predicted how well the patient responded to the treatment.
Researchers turned white blood cells called neutrophils into drug-smuggling “neutrobots,” which penetrated the blood-brain barrier to treat brain cancer in mice.
The cancer researcher and executive vice president of AstraZeneca’s oncology research and development is well known for his role in the development of pivotal breast cancer therapies.
The Scientist’s Creative Services Team | 1 min read
In this webinar, Shaye Hagler will discuss the unexplored capabilities of ChipCytometryTM Spatial Multiplexing Technology for advancing spatial biology research.
Mice that experienced heart attacks underwent a large-scale shift in their immune systems that allowed cancer to flourish, perhaps explaining the observation in patients.
A cancer researcher with a talent for leadership, Marks turned the Memorial Sloan Kettering Cancer Center into one of the world’s foremost oncology research institutions.
The Scientist’s Creative Services Team and Vector Laboratories | 1 min read
Changes to protein glycosylation play a major role in dictating cancer progression and prognosis, but could they also present biomarkers or therapeutic targets?